Raptiva to be Withdrawn from US Market
Posted in Uncategorized on April 10th, 2009 No Comments »
From a Medscape Alert:
April 9, 2009 — Efalizumab (Raptiva, Genentech, Inc) is undergoing a voluntary, phased withdrawal in US markets because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML).
Efalizumab will no longer be available in the United States after June 8, 2009, and healthcare providers are being asked not to initiate […]